GAM
PGNX

Gotham Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Gotham Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-33,737
Closed -$248K – 1109
2017
Q3 		$248K Sell
33,737
-273,656
-89% -$1.74M ﹤0.01% 839
2017
Q2 		$2.09M Sell
307,393
-369,398
-55% -$2.73M 0.03% 512
2017
Q1 		$6.39M Buy
676,791
+147,177
+28% +$1.47M 0.08% 335
2016
Q4 		$4.58M Buy
529,614
+480,741
+984% +$3.55M 0.06% 398
2016
Q3 		$309K Buy
+48,873
New +$295K ﹤0.01% 779

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $637M AUM 39.08% 1-Year Est. Return

Gotham Asset Management's PGNX Position: Q4 2017 in Review

Gotham Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2017, closing a stake of 33,737 shares — an estimated $248K sold.

Gotham Asset Management first reported a position in PGNX in Q3 2016 and held it in 5 quarters. The position peaked at $6.39M in Q1 2017. 153 funds tracked by Wall St. Rank hold PGNX as of Q4 2017.

  • Gotham Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Gotham Asset Management sold 33,737 Progenics Pharmaceuticals Inc shares in Q4 2017, an estimated $248K.
  • Gotham Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q3 2016 and held it in 5 quarters.
  • Gotham Asset Management's Progenics Pharmaceuticals Inc position peaked at $6.39M in Q1 2017.
  • 153 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2017.

Based on Gotham Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.